UNSPSC 51112021: Palbociclib

A kinase inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women or fulvestrant in women with disease progression following endocrine therapy.

UNSPSC 51112021 Palbociclib, a Commodity code, covers pharmaceutical procurement activity in which state and local governments acquire this specific cancer therapeutic — a cyclin-dependent kinase 4/6 inhibitor used in breast cancer treatment — typically through state Medicaid programs, state employee health plans, county health departments, and regional health authorities. The scope of work centers on direct pharmaceutical acquisition, contract negotiations with manufacturers or authorized distributors, and integration into formulary and prior-authorization workflows. State purchasing agencies and health benefit administrators are the primary issuing bodies under this code, with Medicaid agencies and centralized pharmacy procurement offices driving most activity.

The Texas Health and Human Services Commission posted the sole recent opportunity on this code: Request for Information No. HHS0017013, issued April 3, 2026, to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI seeks market intelligence on direct contracting models between state pharmacy benefit programs and pharmaceutical manufacturers outside traditional pharmacy benefit manager, group purchasing organization, and wholesaler arrangements, with emphasis on vendors' experience negotiating net-pricing models and implementing value-based agreements with self-insured employers and government health plans. The RFI is exploratory and information-gathering in nature; no award value, formal competitive timeline, or formal evaluation criteria are specified. Activity under this code remains sparse and concentrated in Texas Medicaid procurement at this stage.